Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P35555: Variant p.Cys926Arg

Fibrillin-1
Gene: FBN1
Feedback?
Variant information Variant position: help 926 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Cysteine (C) to Arginine (R) at position 926 (C926R, p.Cys926Arg). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from medium size and polar (C) to large size and basic (R) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -3 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description: help In MFS; enhances proteolytic degradation. Any additional useful information about the variant.


Sequence information Variant position: help 926 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 2871 The length of the canonical sequence.
Location on the sequence: help TQCEDIDECEVFPGVCKNGL C VNTRGSFKCQCPSGMTLDAT The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human                         TQCEDIDECEVFPGVCKNGLCVNTRGSFKCQCPSGMTLDAT

Mouse                         TQCEDINECEVFPGVCKNGLCVNSRGSFKCECPNGMTLDAT

Pig                           TQCEDIDECEVFPGVCKNGLCVNSKGSFKCQCPNGMTLDAT

Bovine                        TQCEDIDECEVFPGVCKNGLCVNSKGSFKCQCPSGMTLDAT

Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 45 – 2731 Fibrillin-1
Domain 910 – 951 EGF-like 14; calcium-binding
Disulfide bond 914 – 926
Disulfide bond 921 – 935
Beta strand 921 – 929



Literature citations
Fifteen novel FBN1 mutations causing Marfan syndrome detected by heteroduplex analysis of genomic amplicons.
Nijbroek G.; Sood S.; McIntosh I.; Francomano C.A.; Bull E.; Pereira L.; Ramirez F.; Pyeritz R.E.; Dietz H.C.;
Am. J. Hum. Genet. 57:8-21(1995)
Cited for: VARIANTS MFS TYR-129; PHE-166; CYS-746; ARG-926; ARG-1013; LYS-1073; SER-1382 AND ARG-1928; Consequences of cysteine mutations in calcium-binding epidermal growth factor modules of fibrillin-1.
Vollbrandt T.; Tiedemann K.; El-Hallous E.; Lin G.; Brinckmann J.; John H.; Baetge B.; Notbohm H.; Reinhardt D.P.;
J. Biol. Chem. 279:32924-32931(2004)
Cited for: CHARACTERIZATION OF VARIANTS MFS CYS-627; GLY-750 AND ARG-926;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.